ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

ClinicalTrials.gov ID: NCT06693843

Public ClinicalTrials.gov record NCT06693843. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) With at Least One Weight-related Comorbidity

Study identification

NCT ID
NCT06693843
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Enrollment
220 participants

Conditions and interventions

Interventions

  • Aleniglipron Drug
  • Aleniglipron or Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 79 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 27, 2024
Primary completion
Oct 23, 2025
Completion
Jul 31, 2026
Last update posted
Apr 27, 2026

2024 – 2026

United States locations

U.S. sites
39
U.S. states
21
U.S. cities
36
Facility City State ZIP Site status
ACCESS Research Site Phoenix Arizona 85044
ACCESS Research Site Anaheim California 92801
ACCESS Research Site Los Angeles California 90057
ACCESS Research Site Montclair California 91763
ACCESS Research Site Rancho Cucamonga California 91730
ACCESS Research Site Sacramento California 95821
ACCESS Research Site Spring Valley California 91978
ACCESS Research Site Honolulu Hawaii 96814
ACCESS Research Site Chicago Illinois 60602
ACCESS Research Site Chicago Illinois 60637
ACCESS Research Site Evanston Illinois 60201
ACCESS Research Site Muncie Indiana 47304
ACCESS Research Site Valparaiso Indiana 46383
ACCESS Research Site West Des Moines Iowa 50265
ACCESS Research Site Baton Rouge Louisiana 70808
ACCESS Research Site Richfield Minnesota 55423
ACCESS Research Site City of Saint Peters Missouri 63303
ACCESS Research Site Hazelwood Missouri 63042
ACCESS Research Site Springfield Missouri 65807
ACCESS Research Site Albany New York 12203
ACCESS Research Site Binghamton New York 13905
ACCESS Research Site Brooklyn New York 10016
ACCESS Research Site Rochester New York 14609
ACCESS Research Site Wilmington North Carolina 28403
ACCESS Research Site Cincinnati Ohio 45219
ACCESS Research Site Norman Oklahoma 73069
ACCESS Research Site Medford Oregon 97504
ACCESS Research Site Pittsburgh Pennsylvania 15236
ACCESS Research Site Moncks Corner South Carolina 29461
ACCESS Research Site Chattanooga Tennessee 37421
ACCESS Research Site Austin Texas 78704
ACCESS Research Site Austin Texas 78731
ACCESS Research Site Dallas Texas 75226
ACCESS Research Site Dallas Texas 75243
ACCESS Research Site Mesquite Texas 75149
ACCESS Research Site Shavano Park Texas 78231
ACCESS Research Site West Jordan Utah 84088
ACCESS Research Site Winchester Virginia 22601
ACCESS Research Site Morgantown West Virginia 26505

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06693843, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 27, 2026 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06693843 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →